Athlone company bought by Almac Group

Athlone company BioClin Laboratories has been acquired by the Almac Group.

BioClin, which was established in 2002, is located at the IDA Business Park in Garrycaslte. The acquisition was announced this afternoon.

Almac Group is a global contract development and manufacturing organisation and also owns Monksland-based Arran Chemical Company.

BioClin is internationally recognised for providing expert analytical services and rapid reporting of data to support drug development and product release. Its bespoke 14,000sq ft modern facility significantly increases Almac’s analytical capacity and perfectly complements its existing business enabling strategic expansion and greater ability to serve clients’ needs globally. 

The acquisition will see BioClin’s analytical experts join Almac Sciences’ strong network of almost 600 employees across multiple sites in Europe and North America.

Almac also recently completed significant expansion of its existing analytical facilities at its global headquarter site in Northern Ireland with the creation of a new, bespoke, MHRA approved laboratory.

 News of this acquisition comes just days after announcing a multi-million euro expansion of Almac owned, Arran Chemical Company, also based in Athlone, which substantially increased Almac’s manufacturing capacity for fine chemicals, pharmaceutical intermediates and advanced building blocks.

BioClin is internationally recognised for providing expert analytical services including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing and GLP bioanalysis. The company also boasts Ireland’s leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory.

Dr Stephen Barr, Managing Director, Almac Sciences, said: “We are delighted to announce this acquisition demonstrating further commitment to strategic growth and development of our global business. Adding BioClin’s highly complementary analytical capacity and technical expertise to our existing capabilities, we are able to broaden our service offerings and address our global clients’ growing demands for a high quality, integrated, efficient service. We look forward to working with the BioClin team and plan to invest significantly in this facility. This is an exciting development and sets the pace for future growth.”

Mary Burke, Managing Director, BioClin Laboratories commented: “We are very pleased to join Almac. With our shared values for outstanding quality, expertise and innovation we see this as an excellent strategic fit for BioClin enabling us to expand and deliver an enhanced range of analytical solutions to an international client market.”